In the primary tumor, very few CD11b/Ly6Cmed/Ly6G+ cells (1.1±0.2%) could be detected relative to CD11b/Ly6Chi/Ly6G- cells (19.7±1.9%) (Fig 6B). This evidence concerns the gene ITGAM and neoplasm.